An intranasal bivalent vaccine induces antigen-specific humoral and Th1/Th17 cellular immunity and protects young and aged mice against MRSA and Pseudomonas aeruginosa skin and soft tissue infections
Infection and Immunity · 2026
DOI: 10.1128/iai.00355-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2026. Verfasst von Suhrid Maiti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Th1 Cells, Th17 Cells, Pseudomonas Infections. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) are ESKAPE pathogens that are responsible for severe skin and soft tissue infections (SSTIs), particularly in the elderly and those with immunocompromising conditions. Rising rates of methicillin-resistant S. aureus (MRSA) and carbapenem-resistant PA have rendered standard antibiotics less effective. Unfortunately, there are currently no licensed vaccines for either pathogen. To address this need, we developed a bivalent intranasal (IN) vaccine formulation combining L-PaF, a fusion of PA T3SS proteins PcrV and PopB, with the mucosal adjuvant LTA1, NEAT2 (N2), the protective heme-transporting domain of SA IsdB protein, and a novel TLR-4 agonist, which is a detoxified lipid A analog designated Bacterial Enzymatic Combinatorial Chemistry 438 (BECC438b), formulated in an oil-in-water medImmune emulsion (ME). Mice immunized with L-PaF/ME/N2/BECC438b generated robust antigen-specific IgG and IgA responses, which correlated with strong opsonophagocytic killing of both MRSA and PA strains. Vaccination also induced interleukin IL-17A, IL-2, and IL-22 responses in spleen cells from both young and elderly mice, supporting Th1/Th17-mediated immunity. In stringent murine SSTI models, immunized animals exhibited significantly reduced dermonecrosis, abscess volume, and bacterial burden, with approximately a 10-fold reduction in abscess CFUs compared to non-immunized controls. Notably, significant protection was observed in both young and elderly mice despite age-related immunosenescence, with elderly vaccinated animals showing substantially reduced abscess formation and bacterial burden relative to non-immunized controls. These results suggest that the bivalent L-PaF/ME/N2/BECC438b formulation has potential as a broad-spectrum vaccine against both MRSA- and PA-mediated SSTIs across different age groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
- Department of Pathobiology & Integrative Biomedical Sciences, University of Missouri, Columbia, Missouri, USA.
ORCID-Profile: Suhrid Maiti, Ti Lu, Wendy L Picking
Förderung
- NIAID NIH HHS
Zitieren
APA
Maiti, S., Lu, T., Dietz, Z. K., Whittier, S. K., Picking, W. D., & Picking, W. L. (2026). An intranasal bivalent vaccine induces antigen-specific humoral and Th1/Th17 cellular immunity and protects young and aged mice against MRSA and Pseudomonas aeruginosa skin and soft tissue infections. Infection and Immunity. https://doi.org/10.1128/iai.00355-26
Vancouver
Maiti S, Lu T, Dietz ZK, Whittier SK, Picking WD, Picking WL. An intranasal bivalent vaccine induces antigen-specific humoral and Th1/Th17 cellular immunity and protects young and aged mice against MRSA and Pseudomonas aeruginosa skin and soft tissue infections. Infection and Immunity. 2026. doi:10.1128/iai.00355-26
BibTeX
@article{Maiti2026,
author = {Maiti, Suhrid and Lu, Ti and Dietz, Zackary K and Whittier, Sean K and Picking, William D and Picking, Wendy L},
title = {An intranasal bivalent vaccine induces antigen-specific humoral and Th1/Th17 cellular immunity and protects young and aged mice against MRSA and Pseudomonas aeruginosa skin and soft tissue infections},
journal = {Infection and Immunity},
year = {2026},
doi = {10.1128/iai.00355-26}
}
EUVIMED